MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
March 29, 2007
Michael P. Cecil
Stents on Trial New study results could affect stent sales -- at least in the short term. mark for My Articles similar articles
BusinessWeek
July 18, 2005
John Carey
Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives. mark for My Articles similar articles
BusinessWeek
October 9, 2006
John Carey
"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots. mark for My Articles similar articles
BusinessWeek
August 8, 2005
Amy Barrett
BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals. mark for My Articles similar articles
The Motley Fool
December 13, 2006
Stephen Albainy-Jenei
The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 31, 2006
Michael P. Cecil
An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note. mark for My Articles similar articles
BusinessWeek
September 9, 2010
Michelle Cortez
Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots mark for My Articles similar articles
BusinessWeek
October 29, 2007
Arlene Weintraub
Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations mark for My Articles similar articles
BusinessWeek
June 9, 2009
John Carey
Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions mark for My Articles similar articles
The Motley Fool
September 25, 2008
Brian Orelli
Uh-Oh, Stent Makers Drugs are just as good as stents. mark for My Articles similar articles
The Motley Fool
October 25, 2007
Brian Orelli
Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them? mark for My Articles similar articles
Managed Care
February 2007
Maggie Mahar
Why Market Competition Will Not Mend Our Health Care System Doctors have a saying: 'Half of what we know is wrong.' In which half is the conventional wisdom that competition is society's best hope for improving quality and controlling costs? mark for My Articles similar articles
The Motley Fool
September 17, 2007
Brian Orelli
Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales? mark for My Articles similar articles
Managed Care
June 2006
Tom Pope
Hard to Curb Overuse of Drug-Eluting Stents Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused. mark for My Articles similar articles
Managed Care
July 2003
Thomas Morrow
Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money. mark for My Articles similar articles
The Motley Fool
June 1, 2005
Stephen D. Simpson
Stent Wars: Revenge of the Bypass A new study supports a long-held belief that bypass surgery is better than using stents. What does it mean for stent makers and investors? mark for My Articles similar articles
BusinessWeek
April 17, 2006
Amy Barrett
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. mark for My Articles similar articles
BusinessWeek
October 9, 2006
Boston Scientific's Double Bypass First, quality problems with its defibrillators. Now, doubts about the safety of Boston Scientific's coated stents mark for My Articles similar articles
BusinessWeek
June 20, 2005
Spencer E. Ante
Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery. mark for My Articles similar articles
Health
July 2007
Curt Pesmen
Surgery to Avoid #3: Angioplasty A new study has found that heart medication is just as effective as this invasive surgery. mark for My Articles similar articles
The Motley Fool
March 22, 2004
Seth Jayson
Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers? mark for My Articles similar articles
Fast Company
February 1, 2008
Amy Feldman
Artery, Heal Thyself Abbott's new absorbable stent could change heart surgery and revive a $5 billion business. mark for My Articles similar articles
Chemistry World
November 7, 2011
Kate McAlpine
Spotting Artery Damage Before a Heart Attack An international team of medical researchers has developed a way to perform a check up on an artery's physical structure and molecular markers of ill health by coupling a catheter with imaging technology. mark for My Articles similar articles
BusinessWeek
October 29, 2007
Arlene Weintraub
When Good Buzz Goes Bad How Xtent is weathering safety worries about medicated stents. mark for My Articles similar articles
The Motley Fool
December 13, 2006
Matthew Crews
Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies. mark for My Articles similar articles
The Motley Fool
March 8, 2005
Stephen D. Simpson
The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents. mark for My Articles similar articles
The Motley Fool
July 19, 2005
Stephen D. Simpson
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. mark for My Articles similar articles
The Motley Fool
May 28, 2009
Brian Orelli
Boston Scientific Back in an Atomic Way Can its tiny stent save the day? mark for My Articles similar articles
The Motley Fool
August 29, 2008
Brian Orelli
Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases. mark for My Articles similar articles
BusinessWeek
September 22, 2003
Faith Arner
When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles. mark for My Articles similar articles
BusinessWeek
October 31, 2005
Spencer E. Ante
Crashing The Stent Party Conor Medsystems is trying to take on Goliaths J&J and Boston Scientific. mark for My Articles similar articles
The Motley Fool
June 30, 2011
Brian Orelli
Medical-Device Makers' Killer: Health-Care Inflation High prices have painted their targets. mark for My Articles similar articles
The Motley Fool
March 31, 2010
Brian Orelli
How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain. mark for My Articles similar articles
The Motley Fool
December 6, 2007
Brian Orelli
An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off? mark for My Articles similar articles
The Motley Fool
May 27, 2010
Brian Orelli
Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve. mark for My Articles similar articles
The Motley Fool
February 1, 2005
Stephen D. Simpson
Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth. mark for My Articles similar articles
American Family Physician
December 15, 2001
Julia Tucker De Sanctis
Percutaneous Interventions for Lower Extremity Peripheral Vascular Disease Peripheral vascular disease is a common condition with variable morbidity affecting mostly men and women older than 50 years. More than 70 percent of patients diagnosed with the disease remain stable or improve with conservative management... mark for My Articles similar articles
The Motley Fool
August 6, 2004
Jeff Hwang
Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share? mark for My Articles similar articles
The Motley Fool
May 14, 2008
Brian Orelli
Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial. mark for My Articles similar articles
The Motley Fool
February 5, 2008
Brian Orelli
Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S. mark for My Articles similar articles
The Motley Fool
October 20, 2009
Robert Steyer
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. mark for My Articles similar articles
The Motley Fool
January 12, 2007
Billy Fisher
Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 8, 2005
Stephen D. Simpson
Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse? mark for My Articles similar articles
The Motley Fool
October 8, 2007
Billy Fisher
Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead. mark for My Articles similar articles
The Motley Fool
April 24, 2007
Ryan Fuhrmann
Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock. mark for My Articles similar articles
The Motley Fool
November 2, 2006
Brian Lawler
Angiotech's Study Troubles The results of recent studies in medical journals have brought the company's forecasts down. Investors, take note. mark for My Articles similar articles
The Motley Fool
February 2, 2004
Alyce Lomax
Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent. mark for My Articles similar articles
The Motley Fool
November 17, 2006
Brian Lawler
Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 19, 2005
Stephen D. Simpson
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. mark for My Articles similar articles
Chemistry World
November 25, 2010
Hayley Birch
Designing safer stents for heart patients A study by UK researchers provides insights into how the body reacts to the metal stents used to wedge open blocked blood vessels in heart patients. mark for My Articles similar articles